Invion ( (AU:IVX) ) just unveiled an update.
Invion Limited has issued 500,000 ordinary shares at $0.200 each, expanding its financial capacity. The company is in early discussions with RMW Cho Group Limited to potentially broaden its rights to Photosoft™ technology, though no definitive agreements have been reached. This development could impact Invion’s market positioning and operational scope within the photodynamic therapy industry.
More about Invion
Invion Limited is a life-science company specializing in the development and research of Photosoft™ technology, aimed at treating various cancers. The company holds licensing rights in Australia and New Zealand, and its research is funded by RMW Cho Group Limited, the technology’s licensor. Invion is listed on the Australian Securities Exchange (ASX: IVX).
YTD Price Performance: 206.00%
Average Trading Volume: 1,055
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $9.19M
For an in-depth examination of IVX stock, go to TipRanks’ Stock Analysis page.